What is the normal tissues morbidity following Helical Intensity Modulated Radiation Treatment for cervical cancer?. Mouttet-Audouard, R.; Lacornerie, T.; Tresch, E.; Kramar, A.; Le Tinier, F.; Reynaert, N.; Leblanc, E.; Narducci, F.; Lartigau, E.; and Nickers, P. Radiother Oncol, 115(3):386–91, June, 2015.
What is the normal tissues morbidity following Helical Intensity Modulated Radiation Treatment for cervical cancer? [link]Paper  doi  abstract   bibtex   
BACKGROUND AND PURPOSE: To report on normal tissues morbidity following IMRT for cervix cancer. MATERIAL AND METHODS: The first 61 patients of a prospective series were included. 50 Gy to the PTV 1(pelvis) and 60 Gy to the PTV 2 (centro-pelvic disease and GTV nodes) were delivered concomitantly in 28 fractions, followed by a brachytherapy boost. For the small bowel, 50 Gy was the maximal dose, while V45 and V40 had to be \textless50 cc and 200 cc, respectively. For the bladder, rectum and sigmoid structures, 60 Gy was the maximal dose, and V45 and V40 had to be \textless20% and \textless50%. Acute and late toxicity data were prospectively collected. RESULTS: The median follow-up period was 40 months (range: 23-60). 30% and 90% of acute and moderate late side effects were reported respectively. Considering the AUC data of the organs at risk (OAR) DVH, late morbidity and doses were significantly linked (p0.03), predominantly between 10 Gy and 40 Gy, considering the small bowel and sigmoid colon. The high dose regions exhibited no significant impact. CONCLUSION: The moderate dose volumes represent the predominant cause of morbidity after IMRT. Prospective trials are thus required to investigate new ways of dose distribution within the OAR.
@article{mouttet-audouard_what_2015,
	title = {What is the normal tissues morbidity following {Helical} {Intensity} {Modulated} {Radiation} {Treatment} for cervical cancer?},
	volume = {115},
	issn = {1879-0887 (Electronic) 0167-8140 (Linking)},
	shorttitle = {What is the normal tissues morbidity following {Helical} {Intensity} {Modulated} {Radiation} {Treatment} for cervical cancer?},
	url = {http://www.ncbi.nlm.nih.gov/pubmed/25746348},
	doi = {10.1016/j.radonc.2015.02.010},
	abstract = {BACKGROUND AND PURPOSE: To report on normal tissues morbidity following IMRT for cervix cancer. MATERIAL AND METHODS: The first 61 patients of a prospective series were included. 50 Gy to the PTV 1(pelvis) and 60 Gy to the PTV 2 (centro-pelvic disease and GTV nodes) were delivered concomitantly in 28 fractions, followed by a brachytherapy boost. For the small bowel, 50 Gy was the maximal dose, while V45 and V40 had to be {\textless}50 cc and 200 cc, respectively. For the bladder, rectum and sigmoid structures, 60 Gy was the maximal dose, and V45 and V40 had to be {\textless}20\% and {\textless}50\%. Acute and late toxicity data were prospectively collected. RESULTS: The median follow-up period was 40 months (range: 23-60). 30\% and 90\% of acute and moderate late side effects were reported respectively. Considering the AUC data of the organs at risk (OAR) DVH, late morbidity and doses were significantly linked (p0.03), predominantly between 10 Gy and 40 Gy, considering the small bowel and sigmoid colon. The high dose regions exhibited no significant impact. CONCLUSION: The moderate dose volumes represent the predominant cause of morbidity after IMRT. Prospective trials are thus required to investigate new ways of dose distribution within the OAR.},
	number = {3},
	journal = {Radiother Oncol},
	author = {Mouttet-Audouard, R. and Lacornerie, T. and Tresch, E. and Kramar, A. and Le Tinier, F. and Reynaert, N. and Leblanc, E. and Narducci, F. and Lartigau, E. and Nickers, P.},
	month = jun,
	year = {2015},
	keywords = {Adult, Aged, Female, Follow-Up Studies, Humans, Middle Aged, Aged, 80 and over, Morbidity, Prospective Studies, *Radiotherapy, Intensity-Modulated/adverse effects, Brachytherapy, Organs at Risk, Uterine Cervical Neoplasms/*radiotherapy},
	pages = {386--91}
}
Downloads: 0